Dr. Janicak is Professor of Psychiatry, Rush University Medical Center, Psychiatric Clinical Research Center, 2150 West Harrison St, Chicago, IL 60612; E-mail: email@example.com.
All faculty and staff in a position to control the content of this CME activity, and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations related to this CME activity.
The author has disclosed that various pharmacological augmentation strategies (antipsychotic polypharmacy, aspirin, bitopertin, celecoxib, citalopram, D-cycloserine, D-serine, duloxetine, estradiol, estrogen, glycine, lamotrigine, minocycline, mirtazapine, N-acetylcysteine, oxytocin, raloxifene, sarcosine, selegiline, and topiramate) for treatment of schizophrenia are discussed on an off-label basis in this article and have not been approved for such use by the U.S. Food and Drug Administration.
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article(s) and complete the quiz and evaluation assessment survey on the enclosed form, answering at least 80% of the quiz questions correctly. This activity expires on August 31, 2014.